Puma Biotechnology, Inc.
PBYIHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Puma Biotechnology, Inc. (PBYI) is listed under Biotechnology. With a market capitalization of $493.0M, it sits in small-cap territory. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Market Cap
$493.0M
Beta
1.23
P/E (TTM)
18.73
P/E (Fwd)
27.29
EPS (TTM)
$0.51
EPS (Fwd)
$0.35
ROE
22.0%
ROA
9.8%
Cash
$93.9M
Total Debt
$4.8M
Free CF
$32.5M
52W Change
109.4%
Annual Financials
Cash vs Debt
Where PBYI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PBYI finished 30.24% above its 150-day moving average ($7.44) and 38.03% above its 200-day moving average ($7.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PBYI overbought or oversold?
At the September 3, 2026 close, PBYI's RSI(14) was 68.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $93.9M in cash and $4.8M in debt, PBYI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $32.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 22.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $228.0M (2022) to $228.4M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Puma Biotechnology, Inc.'s trajectory.